ストックスクリーナーアプリを入手
14.91
15.22%
1.97
プレマーケット:
15.20
0.29
+1.95%
Eyepoint Inc (EYPT) 最新ニュース
Eyepoint Pharmaceuticals appoints Campbell to boost product launches - Traders Union
EyePoint appoints Michael Campbell as chief commercial officer - marketscreener.com
Eyepoint Appoints Michael Campbell As Chief Commercial Officer - TradingView
EyePoint Appoints Michael Campbell as Chief Commercial Officer - The Manila Times
EyePoint Appoints Michael Campbell as Chief Commercial Officer - GlobeNewswire Inc.
Guggenheim reiterates EyePoint stock rating on rival trial data - Investing.com UK
EyePoint Showcases DURAVYU at Biotech Summit, Advances in Retinal Disease Treatment - StocksToTrade
EyePoint reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Eyepoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
EyePoint Pharmaceuticals Teases Mid-2026 DURAVYU Wet AMD Data, Starts Phase III DME Program - MarketBeat
EyePoint, Inc. (EYPT) Stock Analysis: A 177% Potential Upside Beckons For Investors - DirectorsTalk Interviews
EyePoint at Guggenheim Summit: Strategic Insights for 2026 By Investing.com - Investing.com Canada
EYPT: Pivotal wet AMD and DME trials advance, with DURAVYU targeting six-month dosing and strong safety - TradingView
Why is EyePoint Pharmaceuticals Inc. stock going upWall Street Watch & Free Risk Controlled Daily Trade Plans - mfd.ru
Published on: 2026-02-11 23:37:15 - mfd.ru
RBC Capital reiterates Outperform rating on EyePoint stock amid recent decline - Investing.com South Africa
Stocks showing market leadership: EyePoint earns 93 RS rating - MSN
RBC Capital reiterates Outperform rating on EyePoint stock amid recent decline By Investing.com - in.investing.com
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading 7.8% HigherHere's Why - MarketBeat
Quarterly Risk: Will EyePoint Pharmaceuticals Inc outperform tech stocksJuly 2025 Gainers & AI Driven Price Predictions - baoquankhu1.vn
EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
EyePoint, Inc.'s (NASDAQ:EYPT) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors - simplywall.st
Aug Intraday: Is ProShares Trust ProShares UltraPro Short MidCap400 still a buy after recent gainsMarket Movement Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Analysts Are Bullish on These Healthcare Stocks: EyePoint Pharmaceuticals (EYPT), BrightSpring Health Services, Inc. (BTSG) - The Globe and Mail
RSI Alert: EyePoint (EYPT) Now Oversold - Nasdaq
Mizuho reiterates Outperform rating on EyePoint stock amid share weakness By Investing.com - Investing.com Australia
Mizuho reiterates Outperform rating on EyePoint stock amid share weakness - Investing.com
How Eyepoint Pharmaceuticals Inc. (EYPT) Affects Rotational Strategy Timing - Stock Traders Daily
Despite currently being unprofitable, EyePoint (NASDAQ:EYPT) has delivered a 195% return to shareholders over 3 years - Yahoo Finance
EyePoint, Inc. (EYPT) Stock Analysis: A Biotech With A 144% Upside Potential - DirectorsTalk Interviews
Several EyePoint Insiders Sell Shares Sending Potential Negative Signal - 富途牛牛
Federated Hermes Inc. Trims Holdings in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Winners Losers: Should I hold or sell EyePoint Pharmaceuticals Inc now2025 Market Sentiment & Safe Capital Allocation Plans - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and EyePoint Pharmaceuticals (EYPT) - The Globe and Mail
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 5.3%Here's What Happened - MarketBeat
Aug Final Week: How does E2open Parent Holdings Inc. correlate with NasdaqMarket Performance Recap & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Chipmakers Recap: Can EyePoint Pharmaceuticals Inc expand its profit marginsTrade Exit Report & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Trade Recap: What is the long term forecast for EyePoint Pharmaceuticals Inc stockWeekly Profit Summary & High Accuracy Investment Signals - baoquankhu1.vn
(EYPT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Insider Trends: What are analysts price targets for EyePoint Pharmaceuticals IncGDP Growth & Safe Entry Momentum Tips - baoquankhu1.vn
Volatility Watch: Is EyePoint Pharmaceuticals Inc stock overvalued or fairly pricedMarket Performance Recap & High Return Trade Opportunity Guides - baoquankhu1.vn
Aug Reactions: Will URTY stock go up in YEARJuly 2025 Rallies & Weekly High Momentum Picks - baoquankhu1.vn
EyePoint (EYPT) Issues Stock Options to New Employees - GuruFocus
EyePoint, Inc. (EYPT) Stock Analysis: Exploring the 127.80% Potential Upside in a Challenging Market - DirectorsTalk Interviews
EyePoint, Inc. Grants Stock Options to New Employees as Inducement Awards - Quiver Quantitative
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap UpTime to Buy? - MarketBeat
Equities Analysts Issue Forecasts for EYPT Q3 Earnings - MarketBeat
EyePoint, Inc. Provides Corporate Update and Anticipated Milestones for 2026 - VisionMonday.com
Responsive Playbooks and the EYPT Inflection - Stock Traders Daily
Can EyePoint Pharmaceuticals Inc. stock maintain growth trajectory2025 Technical Patterns & Safe Capital Growth Stock Tips - Улправда
Is EyePoint Pharmaceuticals Inc. stock overvalued by current metricsJuly 2025 Weekly Recap & AI Driven Price Predictions - ulpravda.ru
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 4.6%Here's Why - MarketBeat
Will EyePoint Pharmaceuticals Inc. stock remain a Wall Street favoriteGrip and Outsole Review & road comfort picks for daily use - Улправда
4.46%
大文字化:
|
ボリューム (24 時間):